PURPOSE OF REVIEW: Niacin has been used for more than 50 years in the management of atherosclerosis and is associated with improved patient outcomes. The routine use of niacin has been superseded in recent years with the advent of newer lipid-modulating interventions. Recently, however, there has been a renewed interest in its use due to the appreciation of its many beneficial effects on atherosclerosis and endothelial function, both 'lipid-targeted' and 'pleiotropic'. This review will consider the effects of niacin in the setting of clinical trials and will critically evaluate proposed mechanisms of action. RECENT FINDINGS: The identification of the GPR109A receptor has promoted a greater insight into niacin's mechanism of action, with demonstrated beneficial effects on endothelial function and inflammation, in addition to its lipid modulation role. SUMMARY: Whether niacin itself is used routinely in the future will depend on the outcomes of two large outcome trials (AIM-HIGH and HPS2-THRIVE). In the future, however, with even better understanding of niacin pharmacology, new drugs may be able to be engineered to capture aspects of niacin that capitalize on the benefits more specifically and also more selectively, to avoid troublesome side-effects.
PURPOSE OF REVIEW: Niacin has been used for more than 50 years in the management of atherosclerosis and is associated with improved patient outcomes. The routine use of niacin has been superseded in recent years with the advent of newer lipid-modulating interventions. Recently, however, there has been a renewed interest in its use due to the appreciation of its many beneficial effects on atherosclerosis and endothelial function, both 'lipid-targeted' and 'pleiotropic'. This review will consider the effects of niacin in the setting of clinical trials and will critically evaluate proposed mechanisms of action. RECENT FINDINGS: The identification of the GPR109A receptor has promoted a greater insight into niacin's mechanism of action, with demonstrated beneficial effects on endothelial function and inflammation, in addition to its lipid modulation role. SUMMARY: Whether niacin itself is used routinely in the future will depend on the outcomes of two large outcome trials (AIM-HIGH and HPS2-THRIVE). In the future, however, with even better understanding of niacin pharmacology, new drugs may be able to be engineered to capture aspects of niacin that capitalize on the benefits more specifically and also more selectively, to avoid troublesome side-effects.
Authors: Eric P Plaisance; Martina Lukasova; Stefan Offermanns; Youyan Zhang; Guoqing Cao; Robert L Judd Journal: Am J Physiol Endocrinol Metab Date: 2009-01-13 Impact factor: 4.310
Authors: Shobha H Ganji; S Tavintharan; Daming Zhu; Yiding Xing; Vaijinath S Kamanna; Moti L Kashyap Journal: J Lipid Res Date: 2004-07-16 Impact factor: 5.922
Authors: V Manninen; M O Elo; M H Frick; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen Journal: JAMA Date: 1988-08-05 Impact factor: 56.272
Authors: Alan Wise; Steven M Foord; Neil J Fraser; Ashley A Barnes; Nabil Elshourbagy; Michelle Eilert; Diane M Ignar; Paul R Murdock; Klaudia Steplewski; Andrew Green; Andrew J Brown; Simon J Dowell; Philip G Szekeres; David G Hassall; Fiona H Marshall; Shelagh Wilson; Nicholas B Pike Journal: J Biol Chem Date: 2003-01-09 Impact factor: 5.157
Authors: Janet E Digby; Eileen McNeill; Oliver J Dyar; Vincent Lam; David R Greaves; Robin P Choudhury Journal: Atherosclerosis Date: 2009-08-31 Impact factor: 5.162
Authors: Vincent Dunet; Juan Ruiz; Gilles Allenbach; Paola Izzo; Richard W James; John O Prior Journal: EJNMMI Res Date: 2011-11-18 Impact factor: 3.138